ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 719

Men and Sexual Function: An Overlooked Issue in Systemic Lupus Erythematosus

Jonathan Campos-Guzmán1, Ana Barrera-Vargas1, Diana Gómez-Martín2, Jorge Alcocer-Varela2, Samuel Govea-Peláez1, Miguel Angel Gómez-Sámano3, Daniel Cuevas-Ramos3, Diana Marcela Padilla-Ortíz4 and Javier Merayo-Chalico1, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Universidad de la Sabana, Bogotá, Colombia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Sexuality and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Whereas SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies regarding sexual aspects in women with SLE, but information about sexual function in male patients is quite scant. The impact that the SLE-associated physical and psychological aspects have in these patients has not been previously addressed.

 

Methods:

We performed a transversal study in a third-level referral center in Mexico City (between January and May 2018). We included men aged ≥ 16 years who fulfilled ACR criteria for SLE and who were sexually active in the previous six months. Patients with other autoimmune diseases (except for APS) or chronic viral infections were excluded. All subjects answered the International Index of Erectile Function-15 (IIEF-15) and the SF-36 (which determines generic health-related quality of life) questionnaires. Other clinical, serological and demographic variables were measured. Oxidized LDL was quantified by ELISA.

Results:

We included 73 male SLE patients. Mean age was 37.8 ± 2.7 years and disease duration was 9.0 ± 7.3 years. SLEDAI score at the time of the study was 4.3 ± 4.1 points; most patients (87.7%) were taking immunosuppressive therapy. Comorbidities were present in 54.7% of subjects, with dyslipidemia and hypertension being the most prevalent (31.5% each).

Global IIEF-15 score was 56.4 ± 15.2 (range 5-75 points) and global SF-36 score was 70.1 ± 12.9 (range 0-100 points). There was a positive correlation between both scores (see Fig. 1). There was also a weak correlation between oxidized LDL levels and global IIEF-15 (r=0.321, p=0.036). Regarding erectile function, 37 subjects (50%) had some degree of dysfunction. These patients were older (34.7 ± 12.1 vs 40.9 ± 12.7 years, p=0.037), had a lower education degree (p=0.002) and a higher prevalence of type 2 diabetes mellitus (p=0.016) than those without erectile dysfunction. The rest of the variables are shown in Table 1.

Interestingly, 86% of patients said they would be willing to consult a specialist if any degree of sexual dysfunction was detected.

Conclusion:

Global sexual function, and especially erectile function, is impaired in men with SLE. Most patients with sexual dysfunction are young and sexually active, and this should be considered by their rheumatologists, in order to inquire about this issue in regular visits. Further research is required to determine the physiopathogenic mechanisms underlying this condition, but endothelial damage and SLE-associated neuropsychological features could play a role.

Table 1

Variable

Mean ± SD

Demographic

Age (years)

37.8 ± 12.7

Body mass index (m2/kg)

26.6 ± 4.8

Less than 10 years of schooling (n, %)

17/73 (23.2)

Time since SLE diagnosis (years)

9.0 ± 7.3

Clinical Features

Total score IIEF-15 (reference interval: 5-75 points)

56.47 ± 15.2

Erectile function (reference interval: 1-30 points)

22.68 ± 7.6

Intercourse satisfaction (reference interval: 0-15 points)

10.4 ± 3.6

Orgasmic function (reference interval: 0-10 points)

7.7 ± 2.9

Sexual desire (reference interval: 2-10 points)

7.4 ± 1.8

Overall satisfaction (reference interval: 2-10 points)

8.1 ± 1.6

Total score SF-36 (reference interval: 0-100 points)

70.14 ± 12.9

Physical component summary score (reference interval: 0-100 points)

72.2 ± 17.6

Mental component summary score (reference interval: 0-100 points)

68.0 ± 11.2

Secondary antiphospholipid syndrome (n, %)

22/73 (30.1)

SLEDAI score (points)

4.3 ± 4.1

Others comorbidities (n, %)

40/73 (54.7)

Laboratory features

Hemoglobin (mg/dl)

15.4 ± 2.43

Leukocytes (mm3) (x103)

5.69 ± 2.2

Absolute lymphocyte count (mm3)

1333.5 ± 760.6

Absolute neutrophil count (mm3)

3661.3 ± 1759.4

Neutrophil-to-lymphocyte ratio 

3.9 ± 5.7

Platelets (cells/ɥl) (x103)

216.3 ± 77.2

Serum creatinine (mg/dl)

1.4 ± 1.7

C3 levels (reference interval:87-200 mg/dl)

104.9 ± 32.8

C4 levels (reference interval: 19-52 mg/dl)

19.5 ± 11.6

Anti-dsDNA antibodies (reference interval: ≤9.6 UI/ml)

249.1 ± 796.0

Use of immunosuppressive treatment (n, %)

64/73 (87.7)

Prednisone (n, %)

41/73 (56.2)

Current dose (mg/day)

5.30 ± 7.9

Azathioprine (n, %)

26/73 (35.6)

Current dose (mg/day)

36.3 ± 54.8

Antimalarial (n, %)

48/73 (65.8)

Current dose (mg/day)

150.3 ± 123

Mycophenolate mofetil (n, %)

27/73 (37)

Current dose (mg/day)

616.4 ± 887.9

Cyclophosphamide exposure previous 6 months (n, %)

7/73 (9.5)

Cumulative dose (previous 6 months) (mg)

417 ± 1466

Anticoagulation (n, %)

11/73 (15.0)

Non-immunosuppressive treatment (n, %)

56/73 (76.7)

Figure 1

 


Disclosure: J. Campos-Guzmán, None; A. Barrera-Vargas, None; D. Gómez-Martín, None; J. Alcocer-Varela, None; S. Govea-Peláez, None; M. A. Gómez-Sámano, None; D. Cuevas-Ramos, None; D. M. Padilla-Ortíz, None; J. Merayo-Chalico, None.

To cite this abstract in AMA style:

Campos-Guzmán J, Barrera-Vargas A, Gómez-Martín D, Alcocer-Varela J, Govea-Peláez S, Gómez-Sámano MA, Cuevas-Ramos D, Padilla-Ortíz DM, Merayo-Chalico J. Men and Sexual Function: An Overlooked Issue in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/men-and-sexual-function-an-overlooked-issue-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/men-and-sexual-function-an-overlooked-issue-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology